The Toronto Stock Exchange reports that Satellos Bioscience Inc. will be listed and posted for trading at the open on Feb. 15, 2024. According to the TSX, there will be 112,791,658 common shares issued and outstanding, and 70,349,199 shares reserved for issuance. The shares will trade under the symbol MSCL, in Canadian dollars and with Cusip No. 80401L 30 8.

The TSX reports that Satellos is a biotechnology company dedicated to developing medicines to treat degenerative muscle diseases. The company's lead program is an oral, small-molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. According to the TSX, the company does not anticipate paying cash dividends on its shares in the foreseeable future.

The TSX notes that Satellos has been listed on the TSX Venture Exchange since Aug. 18, 2021, under the symbol MSCL. The company will be delisted from the TSX-V on Feb. 15, 2024, upon the start of trading on the TSX. The temporary market-maker is Research Capital Corp., the transfer agent and registrar is Computershare Investor Services Inc. at its principal office in Vancouver, and the fiscal year-end is Dec. 31.